Kor i helsikkens e sjamannen blitt av ? Sitter han i en annen taxi, og ler på veien til banken, mon tro..............


Edison skrev for noen dager siden.....In our view, this amount of a proof-of-concept data will be more than enough to inform the late-stage R&D strategy, but also will be invaluable in partnering discussions. The INITIUM and NIPU trials are already up and running, while the DOVACC and FOCUS trials should start recruiting patients in H121. The result readouts are expected in 2022 and 2023. Proof-of-concept trials carry significant R&D risk (historical pass-through success probabilities are with the 33–54% range). But the pipeline is well diversified now across indications and different combinations and the result readouts are within cash reach, which the investors will find reassuring.